His main research concerns Pharmacology, Pharmacokinetics, Internal medicine, Ritonavir and Indinavir. His Pharmacology research incorporates elements of Antibiotics and Reverse-transcriptase inhibitor. His work carried out in the field of Reverse-transcriptase inhibitor brings together such families of science as Lamivudine, Emtricitabine, Efavirenz and Confidence interval.
His Pharmacokinetics research integrates issues from Antibacterial agent, Rifampicin, Blood plasma and Dosing. The Internal medicine study combines topics in areas such as Gastroenterology, Immunology, Viral load and Nevirapine. His Ritonavir study incorporates themes from High-performance liquid chromatography, Chromatography, Lopinavir, HIV Protease Inhibitor and Atazanavir.
The scientist’s investigation covers issues in Pharmacokinetics, Pharmacology, Internal medicine, Ritonavir and Gastroenterology. His Pharmacokinetics research is multidisciplinary, relying on both Adverse effect, Pharmacotherapy, Zidovudine and Dosing. His research integrates issues of Lamivudine, Efavirenz and Indinavir in his study of Pharmacology.
His research in Lamivudine tackles topics such as Nevirapine which are related to areas like Reverse-transcriptase inhibitor. His study on Internal medicine also encompasses disciplines like
David M. Burger mainly focuses on Pharmacokinetics, Internal medicine, Dosing, Gastroenterology and Drug. His Pharmacokinetics research is multidisciplinary, incorporating perspectives in Pregnancy, Dolutegravir and Urology. His biological study spans a wide range of topics, including Randomized controlled trial, Efavirenz, Pharmacology, Raltegravir and Pediatrics.
His research in Internal medicine intersects with topics in Oncology and Ritonavir. In his study, Lopinavir/ritonavir is inextricably linked to Lopinavir, which falls within the broad field of Ritonavir. His studies deal with areas such as Hepatitis B, Comorbidity and Intensive care medicine as well as Drug.
David M. Burger spends much of his time researching Pharmacokinetics, Internal medicine, Drug, Pregnancy and Dolutegravir. His Pharmacokinetics study combines topics in areas such as Rifampicin, Renal replacement therapy, Disease, Dosing and Pharmacometrics. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Oncology and Therapeutic index.
His study in Dolutegravir is interdisciplinary in nature, drawing from both Therapeutic drug monitoring, Randomized controlled trial, Lamivudine, Univariate analysis and Raltegravir. Many of his studies involve connections with topics such as Pharmacology and Antibiotics. His work deals with themes such as In vivo and In vitro experiment, which intersect with Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel
Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy.
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway.
K. Brinkman;H.J.M. ter Hofstede;D.M. Burger;J.A.M. Smeitink.
Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
Roger J. M. Bruggemann;Jan-Willem C. Alffenaar;Nicole M. A. Blijlevens;Eliane M. Billaud.
Clinical Infectious Diseases (2009)
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Pythia T. Nieuwkerk;Mirjam A. G. Sprangers;David M. Burger;Richard M. W. Hoetelmans.
JAMA Internal Medicine (2001)
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
Albert Tuldra;Carmina R. Fumaz;Ma José Ferrer;Ramon Bayes.
Journal of Acquired Immune Deficiency Syndromes (2000)
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: The effect of gender, race, and CYP2B6 polymorphism
David Burger;Ilse van der Heiden;Charles la Porte;Marchina van der Ende.
British Journal of Clinical Pharmacology (2006)
Antiretroviral drugs and the central nervous system
Roelien H. Enting;Richard M.w. Hoetelmans;Joep M.a. Lange;David M. Burger.
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.
J P Dieleman;I C Gyssens;M E van der Ende;S de Marie.
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
M.J. Boeree;A.H. Diacon;R. Dawson;K. Narunsky.
American Journal of Respiratory and Critical Care Medicine (2015)
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.
C.J.L. la Porte;E.P.H. Colbers;R.J. Bertz;D.S. Voncken.
Antimicrobial Agents and Chemotherapy (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: